



Companies House

for the record

Please complete in typescript,
or in bold black capitals.

CHWP000

288a

APPOINTMENT of director or secretary (NOT for resignation (use Form 288b) or change of particulars (use Form 288c))

Company Number 3671700

Company Name in full OXXON THERAPEUTICS LIMITED

Date of
appointment

Day Month Year
0 1 0 4 2 0 0 4

†Date of
Birth

Day Month Year
2 1 0 3 1 9 5 5

Appointment form Appointment as director ☒

as secretary ☐

Please mark the appropriate box. If appointment is
as a director and secretary mark both boxes.

Notes on completion
appear on reverse.

NAME *Style / Title

DR

*Honours etc

Forename(s)

JOHN

Surname

BROWN

Previous
Forename(s)

Previous
Surname(s)

†† Tick this box if the
address shown is a
service address for
the beneficiary of a
Confidentiality Order
granted under the
provisions of section
723B of the
Companies Act 1985

†† Usual residential
address



Post town

ROYSTON

Postcode SG8 5HD

County / Region

HERTFORDSHIRE

Country UK

†Nationality

BRITISH

†Business occupation DIRECTOR

†Other directorships
(additional space overleaf)

PHARMAGENE PLC

Consent signature

I consent to act as ** director / secretary of the above named company

John R. Brown

Date 4/6/04

A director, secretary etc must sign the form below.

Signed

DR M. Sp...

Date 1/4/04

(**a director / secretary / administrator / administrative receiver / receiver manager / receiver)

You do not have to give any contact
information in the box opposite but if you
do, it will help Companies House to
contact you if there is a query on the
form. The contact information that you
give will be visible to searchers of the



A99 COMPANIES HOUSE 07/07/04 4938

COMPANIES HOUSE

29/06/04

Form April 2002

When you have completed and signed the form please send it to the
Registrar of Companies at:

Companies House, Crown Way, Cardiff, CF14 3UZ DX 33050 Cardiff
for companies registered in England and Wales or
Companies House, 37 Castle Terrace, Edinburgh, EH1 2EB
for companies registered in Scotland

DX 235 Edinburgh
or LP - 4 Edinburgh 2

Company Number 3671700

† Directors only.

† Other directorships

PROTHERICS, ONYVAX LTD,

ACAMBIS PLC, ACAMBIS RESEARCH LTD,

SMALLPOX BIOSECURITY LTD, SCOTTISH BIOMEDICAL LIMITED,

ROSLIN INSTITUTE (EDINBURGH), ROSLIN BIOMED

NOTES

Show the full forenames, NOT INITIALS. If the director or secretary is a corporation or Scottish firm, show the name on surname line and registered or principal office on the usual residential line.

Give previous forenames or surname(s) except:

- for a married woman, the name by which she was known before marriage need not be given.
- for names not used since the age of 18 or for at least 20 years

A peer or individual known by a title may state the title instead of or in addition to the forenames and surname and need not give the name by which that person was known before he or she adopted the title or succeeded to it.

Other directorships.

Give the name of every company incorporated in Great Britain of which the person concerned is a director or has been a director at any time in the past five years.

You may exclude a company which either is, or at all times during the past five years when the person concerned was a director, was

- dormant
- a parent company which wholly owned the company making the return, or
- another wholly owned subsidiary of the same parent company.

Minute of Board Meeting held on 24th February 2004

- i. Confirm that there are no negative tax consequences for current shareholders
- ii. Ensure that this proposal is acceptable to NIF Ventures and Neomed Innovations (and the four biggest shareholders being represented around the Board table)
- iii. Clarify the minimal requirement for Board meetings in the US
- iv. Confirm that Oxxon would still receive maximum tax credits
- v. Confirm that UK employees would still be able to benefit from the EMI share option scheme
- vi. Clarify Dr Williamson's tax situation and resolve it satisfactorily
- vii. Confirm the costs associated with the flip in more detail

3.1.2 Name Change

The Management recommended to the Board of Directors that Oxxon change its name from Oxxon Pharmaccines Ltd to Oxxon Therapeutics Inc. The term 'pharmaccines' coined by GSK as an alternative to 'therapeutic vaccines' has not been adopted by the academic, clinical or business communities and is often confusing.

The Board recommended that the name be changed and instructed Dr Gillespie to effect this through the appropriate procedures.

3.1.3 Shareholder Day

Shareholders were invited to visit Oxxon for a review of the state of the business on the 24th February. It was well received

3.2 Human Resources

Dr Frank Malinoski has signed his Letter of Employment and joins Oxxon on 1st March 2004 as EVP Development and Chief Medical Officer. He will be based in the Boston office.

Two candidates are currently under consideration for the Chief Commercial Officer position.

Oxxon's headcount is now 30.

Dr John Brown PhD, ex-CEO of Acambis, has accepted Oxxon's invitation to join the Board of Directors and has agreed to the compensation package as defined by the Remuneration Committee. An Appointment Letter will be sent to him for signature and his appointment will take effect from the 1st April 2004.

Discussions are ongoing with Mr. Boyd Clarke who is considering Oxxon's offer to join the Board as a non-executive director. He will be invited to speak with Dr Brimblecombe initially and then join Oxxon's Directors for dinner in Boston.

Plans to allow consultants to be part compensated must be revisited in the light of the proposed US 'flip'.